SEARCH

SEARCH BY CITATION

References

  • 1
    Notter RH. Lung surfactants: Basic science and clinical applications. In: ClaudeL, ed. Lung Biology in Health and Disease, 1st ed. New York: Dekker; 2000:207248.
  • 2
    Frerking I, Gunther A, Seeger W, et al. Pulmonary surfactant: Functions, abnormalities and therapeutic options. Intensive Care Med 2001;27:16991717.
  • 3
    Griese M. Pulmonary surfactant in health and human lung diseases: State of the art. Eur Respir J 1999;13:14551476.
  • 4
    Von Neergard K. Neue Auffassungen uber einen Grundbegriff der Atemmechanik; die Retraktionskraft der Lunge, abhangig von der Oberflachenspannung der Alveolen. Z Ges Exp Med 1929;66:373394.
  • 5
    Pattle RE. Properties, function and origin of the alveolar lining layer. Nature 1955;175:11251126.
  • 6
    Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child 1959;97:517523.
  • 7
    Rossdale PD, Pattle RE, Mahaffey LW. Respiratory distress in a newborn foal with failure to form lung lining fluid. Nature 1967;215:14981499.
  • 8
    Mahaffey LW, Rossdale PD. A convulsive syndrome in newborn foals resembling pulmonary syndrome in newborn infants. Lancet 1959;7085:12231225.
  • 9
    Pattle RE, Rossdale PD, Schock C, et al. The development of the lung and its surfactant in the foal and in other species. J Reprod Fertil Suppl 1975;23:651657.
  • 10
    Clements JA, Avery ME. Lung surfactant and neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998;157:S59S66.
  • 11
    Williams MA, Schmidt AR, Carleton CL, et al. Amniotic fluid analysis for ante-partum foetal assessment in the horse. Equine Vet J 1992;24:236238.
  • 12
    Lester GD. Foal Diseases. In: RobinsonNE, ed. Current Therapy in Equine Medicine 5. Philadelphia, PA: Saunders; 2003:631697.
  • 13
    Kuroki Y, Voelker DR. Pulmonary surfactant proteins. J Biol Chem 1994;269:2594325946.
  • 14
    Rau GA, Vieten G, Haitsma JJ, et al. Surfactant in newborn compared with adolescent pigs: Adaptation to neonatal respiration. Am J Respir Cell Mol Biol 2004;30:694701.
  • 15
    Bernhard W, Hoffmann S, Dombrowsky H, et al. Phosphatidylcholine molecular species in lung surfactant: Composition in relation to respiratory rate and lung development. Am J Respir Cell Mol Biol 2001;25:725731.
  • 16
    Hobo S, Oikawa M, Kuwano A, et al. Effect of transportation on the composition of bronchoalveolar lavage fluid obtained from horses. Am J Vet Res 1997;58:531534.
  • 17
    Hobo S, Yoshihara T, Oikawa M, et al. Surfactant proteins in bronchoalveolar lavage fluid of horses: Assay technique and changes following road transport. Vet Rec 2001;148:7480.
  • 18
    Jahn W. Veranderungen der Surfactantphospholipidzusammensetzung im Tracheobronchialsekret chronisch lungenkranker Pferde. Pferdeheilkunde 1984;1:155158.
  • 19
    Ito S, Hobo S, Kasashima Y. Bronchoalveolar lavage fluid findings in the atelectatic regions of anesthetized horses. J Vet Med Sci 2003;65:10111013.
  • 20
    Morrison KE, Slocombe RF, McKane SA, et al. Functional and compositional changes in pulmonary surfactant in response to exercise. Equine Vet J Suppl 1999;30:6266.
  • 21
    Danlois F, Zaltash S, Johansson J, et al. Pulmonary surfactant from healthy Belgian White and Blue and Holstein Friesian calves: Biochemical and biophysical comparison. Vet J 2003;165:6572.
  • 22
    Christmann U, Welles EG, Waldridge BM, et al. Abnormalities in lung surfactant in horses clinically affected with recurrent airway obstruction (RAO). J Vet Intern Med 2008;22:14521455.
  • 23
    Danlois F, Zaltash S, Johansson J, et al. Very low surfactant protein C contents in newborn Belgian White and Blue calves with respiratory distress syndrome. Biochem J 2000;351:779787.
  • 24
    Wright JR. Clearance and recycling of pulmonary surfactant. Am J Physiol 1990;259:L1L12.
  • 25
    Bernhard W, Haagsman HP, Tschernig T, et al. Conductive airway surfactant: Surface-tension function, biochemical composition, and possible alveolar origin. Am J Respir Cell Mol Biol 1997;17:4150.
  • 26
    Field NT, Gilbert WM. Current status of amniotic fluid tests of fetal maturity. Clin Obstet Gynecol 1997;40:366386.
  • 27
    Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005;5:5868.
  • 28
    Rubio S, Lacaze-Masmonteil T, Chailley-Heu B, et al. Pulmonary surfactant protein A (SP-A) is expressed by epithelial cells of small and large intestine. J Biol Chem 1995;270:1216212169.
  • 29
    Madsen J, Kliem A, Tornoe I, et al. Localization of lung surfactant protein D on mucosal surfaces in human tissues. J Immunol 2000;164:58665870.
  • 30
    Leth-Larsen R, Floridon C, Nielsen O, et al. Surfactant protein D in the female genital tract. Mol Hum Reprod 2004;10:149154.
  • 31
    Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol 2005;42:279287.
  • 32
    Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931962.
  • 33
    Weaver TE, Conkright JJ. Function of surfactant proteins B and C. Annu Rev Physiol 2001;63:555578.
  • 34
    Tokieda K, Whitsett JA, Clark JC, et al. Pulmonary dysfunction in neonatal SP-B-deficient mice. Am J Physiol 1997;273:L875L882.
  • 35
    Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994;93:18601863.
  • 36
    Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 2002;347:21412148.
  • 37
    Orgeig S, Daniels CB, Johnston SD, et al. The pattern of surfactant cholesterol during vertebrate evolution and development: Does ontogeny recapitulate phylogeny? Reprod Fertil Dev 2003;15:5573.
  • 38
    Keating E, Rahman L, Francis J, et al. Effect of cholesterol on the biophysical and physiological properties of a clinical pulmonary surfactant. Biophys J 2007;93:13911401.
  • 39
    West JB. Mechanics of breathing. In: SunB, ed. Respiratory Physiology, the Essentials. Philadelphia, PA: Lippincott Williams and Wilkins; 2005:93120.
  • 40
    Macklem PT, Proctor DF, Hogg JC. The stability of peripheral airways. Respir Physiol 1970;8:191203.
  • 41
    Liu MY, Wang LM, Li E, et al. Pulmonary surfactant will secure free airflow through a narrow tube. J Appl Physiol 1991;71:742748.
  • 42
    Enhorning G, Duffy LC, Welliver RC. Pulmonary surfactant maintains patency of conducting airways in the rat. Am J Respir Crit Care Med 1995;151:554556.
  • 43
    Hills BA, Chen Y. Suppression of neural activity of bronchial irritant receptors by surface-active phospholipid in comparison with topical drugs commonly prescribed for asthma. Clin Exp Allergy 2000;30:12661274.
  • 44
    De Sanctis GT, Tomkiewicz RP, Rubin BK, et al. Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog. Eur Respir J 1994;7:16161621.
  • 45
    Koetzler R, Saifeddine M, Yu Z, et al. Surfactant as an airway smooth muscle relaxant. Am J Respir Cell Mol Biol 2006;34:609615.
  • 46
    Meyer KC, Zimmerman JJ. Inflammation and surfactant. Paediatr Respir Rev 2002;3:308314.
  • 47
    Wright JR. Host defense functions of pulmonary surfactant. Biol Neonate 2004;85:326332.
  • 48
    Wright JR. Pulmonary surfactant: A front line of lung host defense. J Clin Invest 2003;111:14531455.
  • 49
    Chiba H, Pattanajitvilai S, Evans AJ, et al. Human surfactant protein D (SP-D) binds Mycoplasma pneumoniae by high affinity interactions with lipids. J Biol Chem 2002;277:2037920385.
  • 50
    Ferguson JS, Voelker DR, McCormack FX, et al. Surfactant protein D binds to Mycobacterium tuberculosis bacilli and lipoarabinomannan via carbohydrate[ndash]lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. J Immunol 1999;163:312321.
  • 51
    Ferguson JS, Voelker DR, Ufnar JA, et al. Surfactant protein D inhibition of human macrophage uptake of Mycobacterium tuberculosis is independent of bacterial agglutination. J Immunol 2002;168:13091314.
  • 52
    McNeely TB, Coonrod JD. Aggregation and opsonization of type A but not type B Hemophilus influenzae by surfactant protein A. Am J Respir Cell Mol Biol 1994;11:114122.
  • 53
    Holmskov U, Thiel S, Jensenius JC. Collectins and ficolins: Humoral lectins of the innate immune defense. Annu Rev Immunol 2003;21:547578.
  • 54
    Matalon S, Wright JR. Surfactant proteins and inflammation: The yin and the yang. Am J Respir Cell Mol Biol 2004;31:585586.
  • 55
    Wu H. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003;111:15891602.
  • 56
    Schagat TL, Wofford JA, Wright JR. Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol 2001;166:27272733.
  • 57
    Reidy MF, Wright JR. Surfactant protein A enhances apoptotic cell uptake and TGF-beta1 release by inflammatory alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2003;285:L854L861.
  • 58
    Wilsher ML, Hughes DA, Haslam PL. Immunoregulatory properties of pulmonary surfactant: Effect of lung lining fluid on proliferation of human blood lymphocytes. Thorax 1988;43:354359.
  • 59
    Chao W, Spragg RG, Smith RM. Inhibitory effect of porcine surfactant on the respiratory burst oxidase in human neutrophils. Attenuation of p47phox and p67phox membrane translocation as the mechanism. J Clin Invest 1995;96:26542660.
  • 60
    Wu YZ, Medjane S, Chabot S, et al. Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kappaB. Am J Respir Crit Care Med 2003;168:692699.
  • 61
    Baritussio A. Lung surfactant, asthma, and allergens: A story in evolution. Am J Respir Crit Care Med 2004;169:550551.
  • 62
    Veldhuizen R, Possmayer F. Phospholipid metabolism in lung surfactant. Subcell Biochem 2004;37:359388.
  • 63
    Putman E, Creuwels LAJM, Van Golde LM, et al. Surface properties, morphology and protein composition of pulmonary surfactant subtypes. Biochem J 1996;320:599605.
  • 64
    Veldhuizen RAW, Yao LY, Lewis J. An examination of the different variables affecting surfactant aggregate conversion in vitro. Exp Lung Res 1999;25:127141.
  • 65
    Zhang L, Whitsett JA. Molecular basis for surfactant function in ARDS. In: WongHR, ShanleyTP, eds. Molecular Biology of Acute Lung Injury, 1st ed. Boston: Kluwer Academic Publishers; 2001:177192.
  • 66
    Veldhuizen RA, McCaig LA, Akino T, et al. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995;152:18671871.
  • 67
    Ingenito EP, Mora R, Mark L. Pivotal role of anionic phospholipids in determining dynamic behavior of lung surfactant. Am J Respir Crit Care Med 2000;161:831838.
  • 68
    Rodriguez-Capote K, Nag K, Schurch S, et al. Surfactant protein interactions with neutral and acidic phospholipid films. Am J Physiol Lung Cell Mol Physiol 2001;281:L231L242.
  • 69
    Perez-Gil J, Keough KM. Interfacial properties of surfactant proteins. Biochim Biophys Acta 1998;1408:203217.
  • 70
    Enhorning G, Holm BA. Disruption of pulmonary surfactant's aibility to maintain openness of a narrow tube. J Appl Physiol 1993;74:29222927.
  • 71
    Hirche TO, Crouch EC, Espinola M, et al. Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. J Biol Chem 2004;279:2768827698.
  • 72
    Ackerman SJ, Kwatia MA, Doyle CB, et al. Hydrolysis of surfactant phospholipids catalized by phospholipases A2 and eosinophil lysophospholipases causes surfactant dysfunction. Chest Suppl 2003;123:355S.
  • 73
    Seeds MC, Bowton DL, Hite RD, et al. Human eosinophil group IID secretory phospholipase A2 causes surfactant dysfunction. Chest 2003;123:376S377S.
  • 74
    Sweet D, Bevilacqua G, Carnielli V, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome. J Perinat Med 2007;35:175186.
  • 75
    Grenache DG, Gronowski AM. Fetal lung maturity. Clin Biochem 2006;39:110.
  • 76
    Kobzig L, Schoen FJ. The lung. In: CotranRS, KumarV, CollinsT, eds. Pathologic Basis of Disease, 6th ed. Philadelphia, PA: WB Saunders; 1999:673734.
  • 77
    Hamvas A, Nogee L, Mallory GB, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr 1997;130:231239.
  • 78
    Tokieda K, Whitsett JA, Clark JC, et al. Pulmonary dysfunction in neonatal SP-B-deficient mice. Am J Physiol 1997;273:L875L882.
  • 79
    DeMello DE, Heyman S, Phelps DS, et al. Ultrastructure of lung in surfactant protein B deficiency. Am J Respir Cell Mol Biol 1994;11:230239.
  • 80
    Thompson MW. Surfactant protein B deficiency: Insights into surfactant function through clinical surfactant protein deficiency. Am J Med Sci 2001;321:2632.
  • 81
    Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005;33:319327.
  • 82
    Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:13341349.
  • 83
    Gunther A, Ruppert C, Schmidt R, et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001;2:353364.
  • 84
    Davidson WJ, Dorscheid D, Spragg R, et al. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: Results of a meta-analysis. Crit Care 2006;10: R41, 1–9.
  • 85
    Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European consensus conference on acute respiratory distress syndrome: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care 1994;9:7281.
  • 86
    Schmidt R, Markart P, Ruppert C, et al. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res 2007;8:55, 1–11.
  • 87
    Gunther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153:176184.
  • 88
    Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88:19761981.
  • 89
    Hallman M, Spragg R, Harrell JH, et al. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982;70:673683.
  • 90
    Pison U, Obertacke U, Brand M, et al. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J Trauma 1990;30:1926.
  • 91
    Pison U, Seeger W, Buchhorn R, et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989;140:10331039.
  • 92
    Lewis JF, Brackenbury A. Role of exogenous surfactant in acute lung injury. Crit Care Med 2003;31:S324S328.
  • 93
    Kroegel C, Forster M. Pathogenetische Grundlagen des Asthma Bronchiale. In: KroegelC, ed. Asthma Bronchiale, 2nd ed. Stuttgart: Georg Thieme Verlag; 2002:3371.
  • 94
    Kurashima K, Fujimura M, Matsuda T, et al. Surface activity of sputum from acute asthmatic patients. Am J Respir Crit Care Med 1997;155:12541259.
  • 95
    Jarjour NN, Enhorning G. Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant. Am J Respir Crit Care Med 1999;160:336341.
  • 96
    Hohlfeld JM, Ahlf K, Enhorning G, et al. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am J Respir Crit Care Med 1999;159:18031809.
  • 97
    Heeley EL, Hohlfeld JM, Krug N, et al. Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma. Am J Physiol Lung Cell Mol Physiol 2000;278:L305L311.
  • 98
    Wright SM, Hockey PM, Enhorning G, et al. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol 2000;89:12831292.
  • 99
    Hite RD, Seeds MC, Bowton DL, et al. Surfactant phospholipid changes after antigen challenge: A role for phosphatidylglycerol in dysfunction. Am J Physiol Lung Cell Mol Physiol 2005;288:L610L617.
  • 100
    Hite RD, Seeds MC, Safta AM, et al. Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A(2)-mediated surfactant dysfunction. Am J Physiol Lung Cell Mol Physiol 2005;288:L618L624.
  • 101
    Hohlfeld JM, Schmiedl A, Erpenbeck VJ, et al. Eosinophil cationic protein alters pulmonary surfactant structure and function in asthma. J Allergy Clin Immunol 2004;113:496502.
  • 102
    Hohlfeld JM, Erpenbeck VJ, Krug N. Surfactant proteins SP-A and SP-D as modulators of the allergic inflammation in asthma. Pathobiology 2002;70:287292.
  • 103
    Van De Graaf EA, Jansen HM, Lutter R, et al. Surfactant protein A in bronchoalveolar lavage fluid. J Lab Clin Med 1992;120:252263.
  • 104
    Cheng G, Ueda T, Numao T, et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur Respir J 2000;16:831835.
  • 105
    Kurashima K, Ogawa H, Ohka T, et al. A pilot study of surfactant inhalation in the treatment of asthmatic attack. Arerugi 1991;40:160163.
  • 106
    Babu KS, Woodcock DA, Smith SE, et al. Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J 2003;21:10461049.
  • 107
    Ashwood ER. Standards of laboratory practice: Evaluation of fetal lung maturity. National Academy of Clinical Biochemistry. Clin Chem 1997;43:211214.
  • 108
    Ventolini G, Neiger R, Hood D, et al. Update on assessment of fetal lung maturity. J Obstet Gynaecol 2005;25:535538.
  • 109
    Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980;1:5559.
  • 110
    Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993;328:861868.
  • 111
    Jobe AH. Which surfactant for treatment of respiratory-distress syndrome. Lancet 2000;355:13801381.
  • 112
    Bernhard W, Mottaghian J, Gebert A, et al. Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 2000;162:15241533.
  • 113
    Lachmann B. Surfactant Replacement Therapy in Neonatal and Adult Respiratory Distress Syndrome, 1st ed. Berlin: Springer-Verlag; 1987.
  • 114
    Yu S, Harding PG, Smith N, et al. Bovine pulmonary surfactant: Chemical composition and physical properties. Lipids 1983;18:522529.
  • 115
    Hall SB, Wang Z, Notter RH. Separation of subfractions of the hydrophobic components of calf lung surfactant. J Lipid Res 1994;35:13861394.
  • 116
    Body DR. The phospholipid composition of pig lung surfactant. Lipids 1971;6:625629.
  • 117
    Kahn MC, Anderson GJ, Anyan WR, et al. Phosphatidylcholine molecular species of calf lung surfactant. Am J Physiol 1995;269:L567L573.
  • 118
    Christmann U, Livesey LC, Taintor JS, et al. Lung surfactant function and composition in neonatal foals and adult horses. J Vet Intern Med 2006;20:14021407.
  • 119
    Muellenbach RM, Kredel M, Said HM, et al. High-frequency oscillatory ventilation reduces lung inflammation: A large-animal 24-h model of respiratory distress. Intensive Care Med 2007;33:14231433.
  • 120
    Batchinsky AI, Martini DK, Jordan BS, et al. Acute respiratory distress syndrome secondary to inhalation of chlorine gas in sheep. J Trauma 2006;60:944956; discussion 956–957.
  • 121
    Nieman GF, Gatto LA, Paskanik AM, et al. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs. Crit Care Med 1996;24:10251033.
  • 122
    Eigenmann UJ, Schoon HA, Jahn D, et al. Neonatal respiratory distress syndrome in the calf. Vet Rec 1984;114:141144.
  • 123
    Vestweber JG. Respiratory problems of newborn calves. Vet Clin North Am Food Anim Pract 1997;13:411424.
  • 124
    Pirie HM, Selman IE. Acute respiratory distress syndrome in a premature calf. Vet Rec 1969;85:293294.
  • 125
    Hill JR, Chavatte P. Pregnancy and neonatal care of cloned animals. In: CibelliJB, ed. Principles of Cloning. Amsterdam: Academic Press; 2002:247262.
  • 126
    Hill JR, Roussel AJ, Cibelli JB, et al. Clinical and pathologic features of cloned transgenic calves and fetuses (13 case studies). Theriogenology 1999;51:14511465.
  • 127
    Fecteau ME, Palmer JE, Wilkins PA. Neonatal care of high-risk cloned and transgenic calves. Vet Clin North Am Equine Pract 2005;21:637653.
  • 128
    Zaremba W, Grunert E, Aurich JE. Prophylaxis of respiratory distress syndrome in premature calves by administration of dexamethasone or a prostaglandin F2 alpha analogue to their dams before parturition. Am J Vet Res 1997;58:404407.
  • 129
    Buczinski SM, Fecteau G, Lefebvre RC, et al. Fetal well-being assessment in bovine near-term gestations: Current knowledge and future perspectives arising from comparative medicine. Can Vet J 2007;48:178183.
  • 130
    Gordon I. Reproductive Technologies in Farm Animals. Wallingford, UK: CABI Publishing; 2004.
  • 131
    Kordts E, Jochle W. Induced parturition in dairy cattle: A comparison of a corticoid (flumethasone) and a prostaglandin (PGF2a) in different age groups. Theriogenology 1975;3:171178.
  • 132
    Lewing FJ, Proulx J, Mapletoft RJ. Induction of parturition in the cow using cloprostenol and dexamethasone in combination. Can Vet J 1985;26:317322.
  • 133
    Baker AA, Copland RS, Rival MD, et al. The induction of parturition as an aid in the management of dystocia in beef herds. Aust Vet J 1988;65:3233.
  • 134
    Johnston NE, Stewart JA. The effect of glucocorticoids and prematurity on absorption of colostral immunoglobulin in the calf. Aust Vet J 1986;63:191192.
  • 135
    Peters AR, Poole DA. Induction of parturition in dairy cows with dexamethasone. Vet Rec 1992;131:576578.
  • 136
    Schmidt M, Sangild PT, Blum JW, et al. Combined ACTH and glucocorticoid treatment improves survival and organ maturation in premature newborn calves. Theriogenology 2004;61:17291744.
  • 137
    Bo GA, Fernandez M, Barth AD, et al. Reduced incidence of retained placenta with induction of parturition in the cow. Theriogenology 1992;38:4561.
  • 138
    Karapinar T, Dabak M. Treatment of premature calves with clinically diagnosed respiratory distress syndrome. J Vet Intern Med 2008;22:462466.
  • 139
    Ikegami M, Adams FH, Towers B, et al. The quantity of natural surfactant necessary to prevent the respiratory distress syndrome in premature lambs. PediatrRes 1980;14:10821085.
  • 140
    Hurt H, Kattwinkel J, Roth S. Artificial surfactant treatment in lambs with severe respiratory distress syndrome: A controlled study. J Pediatr 1983;102:450453.
  • 141
    Jobe AH, Newnham JP, Moss TJ, et al. Differential effects of maternal betamethasone and cortisol on lung maturation and growth in fetal sheep. Am J Obstet Gynecol 2003;188:2228.
  • 142
    Lewis JF, Ikegami M, Jobe AH, et al. Aerosolized surfactant treatment of preterm lambs. J Appl Physiol 1991;70:869876.
  • 143
    Jacobs H, Jobe A, Ikegami M, et al. Premature lambs rescued from respiratory failure with natural surfactant: Clinical and biophysical correlates. Pediatr Res 1982;16:424429.
  • 144
    Moss TJ, Mulrooney NP, Nitsos I, et al. Intra-amniotic corticosteroids for preterm lung maturation in sheep. Am J Obstet Gynecol 2003;189:13891395.
  • 145
    Mescher EJ, Platzker AC, Ballard PL, et al. Ontogeny of tracheal fluid, pulmonary surfactant, and plasma corticoids in the fetal lamb. J Appl Physiol 1975;39:10171021.
  • 146
    Platzker AC, Kitterman JA, Mescher EJ, et al. Surfactant in the lung and tracheal fluid of the fetal lamb and acceleration of its appearance by dexamethasone. Pediatrics 1975;56:554561.
  • 147
    Benson BJ, Kitterman JA, Clements JA, et al. Changes in phospholipid composition of lung surfactant during development in the fetal lamb. Biochim Biophys Acta 1983;753:8388.
  • 148
    Fujiwara T, Adams FH, Sipos S, et al. “Alveolar” and whole lung phospholipids of the developing fetal lamb lung. Am J Physiol 1968;215:375382.
  • 149
    Meyerholz DK, Kawashima K, Gallup JM, et al. Expression of select immune genes (surfactant proteins A and D, sheep beta defensin 1, and toll-like receptor 4) by respiratory epithelia is developmentally regulated in the preterm neonatal lamb. Dev Comp Immunol 2006;30:10601069.
  • 150
    Benson BJ, Kitterman JA, Clements JA, et al. Changes in phospholipid composition of lung surfactant during development in the fetal lamb. Biocim Biophys Acta 1983;753:8388.
  • 151
    Ballard PL, Ning Y, Polk D, et al. Glucocorticoid regulation of surfactant components in immature lambs. Am J Physiol 1997;273:L1048L1057.
  • 152
    Jobe AH, Moss TJ, Nitsos I, et al. Betamethasone for lung maturation: Testing dose and formulation in fetal sheep. Am J Obstet Gynecol 2007;197:523525.
  • 153
    Menzies PI. Lambing management and neonatal care. In: YoungquistRS, ThrelfallWR, eds. Large Animal Theriogenology. St Louis, MO: Saunders Elsevier; 2007:680695.
  • 154
    Mobini S, Heath AM, Pugh DG. Theriogenology of sheep and goats. In: PughDG, ed. Sheep and Goat Medicine. Philadelphia, PA: WB Saunders; 2002:129186.
  • 155
    Hunt ER. Treatment of pregnancy toxaemia in ewes by induction of parturition. Aust Vet J 1976;52: 338339.
  • 156
    Harman EL, Slyter AL. Induction of parturition in the ewe. J Anim Sci 1980;50:391393.
  • 157
    House JK. The peripartum ruminant. In: SmithB, ed. Large Animal Internal Medicine, 4th ed. St Louis, MO: Mosby Elservier; 2009:248251.
  • 158
    Jobe AH. Animal models of antenatal corticosteroids: Clinical implications. Clin Obstet Gynecol 2003;46:174189.
  • 159
    Jobe A, Ikegami M, Glatz T, et al. Duration and characteristics of treatment of premature lambs with natural surfactant. J Clin Invest 1981;67:370375.
  • 160
    Ikegami M, Ueda T, Absolom D, et al. Changes in exogenous surfactant in ventilated preterm lamb lungs. Am Rev Respir Dis 1993;148:837844.
  • 161
    Cummings JJ, Holm BA, Hudak ML, et al. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis 1992;145:9991004.
  • 162
    Notter RH, Egan EA, Kwong MS, et al. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: Effects of dose, dispersion technique, and gestational age. Pediatr Res 1985;19:569577.
  • 163
    Meyerholz DK, Ackermann MR. Antimicrobial peptides and surfactant proteins in ruminant respiratory tract disease. Vet Immunol Immunopathol 2005;108:9196.
  • 164
    Grubor B, Gallup JM, Meyerholz DK, et al. Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs. Clin Diagn Lab Immunol 2004;11:599607.
  • 165
    Grubor B, Gallup JM, Ramirez-Romero R, et al. Surfactant protein D expression in normal and pneumonic ovine lung. Vet Immunol Immunopathol 2004;101:235242.
  • 166
    Bradley R, Wrathall AE. Barker (neonatal respiratory distress) syndrome in the pig: The ultrastructural pathology of the lung. J Pathol 1977;122:145151.
  • 167
    Gibson EA, Blackmore RJ, Wijeratne WV, et al. The “barker” (neonatal respiratory distress) syndrome in the pig: Its occurrence in the field. Vet Rec 1976;98:476479.
  • 168
    Slauson DO. Naturally occurring hyaline membrane disease syndromes in foals and piglets. J Pediatr 1979;95:889891.
  • 169
    Arvidson G, Astedt B, Ekelund L, et al. Surfactant studies in the fetal and neonatal foal. J Reprod Fertil Suppl 1975;23:663665.
  • 170
    Wilkins PA, Otto CM, Baumgardner JE, et al. Acute lung injury and acute respiratory distress syndromes in veterinary medicine: Consensus definitions: The Dorothy Havemeyer Working Group on ALI and ARDS in Veterinary Medicine. J Vet Emergency Crit Care 2007;17:333339.
  • 171
    Paradis MR. Lecithin/sphingomyelin ratios and phosphatidylglycerol in term and premature equine amniotic fluid. Am Vet Med Forum 1987;5:789792.
  • 172
    Williams MA, Goyert NA, Goyert GL, et al. Preliminary report of transabdominal amniocentesis for the determination of pulmonary maturity in an equine population. Equine Vet J 1988;20:457458.
  • 173
    Williams MA, Wallace SS, Tyler JW, et al. Biochemical characteristics of amniotic and allantoic fluid in late gestational mares. Theriogenology 1993;40:12511257.
  • 174
    Castagnetti C, Mariella J, Serrazanetti GP, et al. Evaluation of lung maturity by amniotic fluid analysis in equine neonate. Theriogenology 2007;67:14551462.
  • 175
    Rota A, Crisci A, Maranghi L, et al. Concentrations of lamellar bodies and the lecithin/sphingomyelin ratio in equine amniotic fluid at the time of delivery. Vet Res Commun 2006;30:20032006.
  • 176
    Alm CC, Sullivan JJ, First NL. The effect of a corticosteroid (dexamethasone), progesterone, oestrogen and prostaglandin F2alpha on gestation length in normal and ovariectomized mares. J Reprod Fertil Suppl 1975;637640.
  • 177
    Jeffcott LB, Rossdale PD. A critical review of current methods for induction of parturition in the mare. Equine Vet J 1977;9:208215.
  • 178
    Ousey JC, Kolling M, Allen WR. The effects of maternal dexamethasone treatment on gestation length and foal maturation in Thoroughbred mares. Anim Reprod Sci 2006;94:436438.
  • 179
    Rossdale PD. Clinical view of disturbances in equine foetal maturation. Equine Vet J Suppl 1993;14: 37.
  • 180
    Rossdale PD, McGladdery AJ, Ousey JC, et al. Increase in plasma progestagen concentrations in the mare after foetal injection with CRH, ACTH or betamethasone in late gestation. Equine Vet J 1992;24:347350.
  • 181
    Freeman K, Simmons R, Wilkins PA, et al. Bronchopulmonary dysplasia in neonatal foals. In: 7th ACVIM Forum, San Diego, CA, 1989: 542545.
  • 182
    Mazan M. Non-infectious respiratory problems. In: ParadisMR, ed. Equine Neonatal Medicine. A Case-Based Approach. Philadelphia, PA: Elsevier Saunders; 2006:135156.
  • 183
    Costa LR, Eades SC, Goad ME, et al. Pulmonary surfactant dysfunction and lung maturation in neonatal foals: Therapy, prevention, and prognosis. Compend Contin Pract Vet 2004;26:460470.
  • 184
    Lester GD. The foal. In: RobinsonNE, ed. Current Therapy in Equine Internal Medicine, 4th ed. Philadelphia, PA: Saunders; 1997:581647.
  • 185
    Perry B. The use of bovine derived surfactant in foals with respiratory distress. In: 11th ACVIM Forum, Washington DC, 1993;189192.
  • 186
    Ainsworth DM. Respiratory therapy in foals. In: 19th ACVIM Forum, Denver, CO, 2001;248249.
  • 187
    Hobo S, Ogasawara Y, Kuroki Y, et al. Purification and biochemical characterization of pulmonary surfactant protein A of horses. Am J Vet Res 1999;60:169173.
  • 188
    Hobo S, Ogasawara Y, Kuroki Y, et al. Purification and biochemical characterization of equine pulmonary surfactant protein D. Am J Vet Res 1999;60:368372.
  • 189
    Hospes R, Hospes BI, Reiss I, et al. Molecular biological characterization of equine surfactant protein A. J Vet Med A Physiol Pathol Clin Med 2002;49:497498.
  • 190
    Kankavi O, Ata A, Akif Ciftcioglu M. Surfactant protein A and D in the reproductive tract of stallion. Theriogenology 2006;66:10571064.
  • 191
    Kankavi O, Ata A, Gungor O. Surfactant proteins A and D in the genital tract of mares. Anim Reprod Sci 2007;98:259270.
  • 192
    Kankavi O, Roberts MS. Detection of surfactant protein A (SP-A) and surfactant protein D (SP-D) in equine synovial fluid with immunoblotting. Can J Vet Res 2004;68:146149.
  • 193
    Humber KA. Near drowning of a gelding. J Am Vet Med Assoc 1988;192:377378.